Skip to content
Oncotarget cover art

All Episodes

Oncotarget — 500 episodes · page 4 of 5

#
Title
301

Adopted Neoplastic Cells and the Consequences of Their Existence

302

ER Expression Multiclonality in DCIS: Clinical & Future Insights

303

Editorial: A Macrophage is a Macrophage is a Macrophage—in Metastasis

304

Aggressive Luminal Breast Cancer: Are Cis-Spliced Fusion Proteins Pathological?

305

Inhibiting Glutamine Metabolism Impacts Tumor Cells or the Microenvironment?

306

Guiding Therapies for HPV Malignancies: Tumor Burden Surrogates

307

Blog: Whole-Genome Doubling and Aneuploidy in Human Cancer

308

CDK9 Inhibitors: A Promising Combination Partner in Treating Hematological Malignancies

309

AGO2 in T-prolymphocytic Leukemia (T-PLL)

310

Epigenetically Guided Cancer Therapy: Targeting H3K27me3 Loss in Pediatric Brain Tumors

311

Multiclonality of Estrogen Receptor Expression in Ductal Carcinoma in Situ (DCIS)

312

Blog: The Obesity Paradox, Metformin and Lung Cancer

313

KIAA0930: A Cachexic Phenotype Inducer in Cancer Cells

314

A Multiplex Assay to Assess Activated p300/CBP in Circulating Prostate Tumor Cells

315

Novel Therapeutic Strategy Against Melanoma: Combined Targeting of Hedgehog Signaling and BRD4

316

Case Report: Intrathoracic Synovial Sarcoma with BRAF V600E Mutation

317

Targeting Ras in Cancer Therapies: Advances in Protein Engineering

318

Cetuximab's Effectiveness and Toxicity in Advanced Cutaneous Squamous Cell Skin Cancer

319

Deciphering Progesterone’s Mechanisms of Action in Breast Cancer

320

Turning Immunosuppressive Tumors to Immunostimulatory: Nerofe and Doxorubicin's Impact

321

ERβ as a Mediator of Estrogen Signaling in Inflammatory Breast Cancer

322

Novel GEM Model Unveils PLK1’s Role in Tumorigenesis

323

Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

324

DPDT Anticancer Activity in Human Colon Cancer HCT116 Cells

325

Targeting GITR in Cancer Immunotherapy – There Is No Perfect Knowledge

326

Metformin's Role in Preventing Metabolic Syndrome During Androgen Deprivation Therapy

327

Oncotarget Sponsors 2023 Ride for Roswell

328

ACSL4: Biomarker, Mediator and Target in Quadruple Negative Breast Cancer

329

LP-284 Targets Non-Hodgkin's Lymphoma and DNA Damage Repair Deficiency

330

Targeting the Src N-Terminal Regulatory Element in Cancer

331

Value of Chemotherapy Post Immunotherapy in Stage IV Non-Small Cell Lung Cancer

332

BORIS Gene Mutation and Expression: Link to Breast Cancer Progression

333

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

334

Can the Creatine Shuttle be Targeted to Fight Colorectal Cancer?

335

Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts

336

HER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic Cancer

337

GPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and the p-mTOR/p53 Axis

338

Targeting Cellular Respiration as a Therapeutic Strategy in Glioblastoma

339

Impact Journals (Oncotarget's Publisher) at SSP 45th Annual Meeting

340

Automated, Accurate Reporting for NGS-Based Clonality Testing

341

Reaching the Brain Through the Groin: A Novel Approach to Brain Cancer

342

Using Cancer Proteomics Data to Identify Gene Candidates for Therapeutic Targeting

343

Role of Biomarkers in Management of Lumps in the Breast

344

LY6 Gene Family: Potential Tumor Antigens and Prognostic Biomarkers in Endometrial Cancer

345

Systemic AL Amyloidosis: Current Approach and Future Direction

346

Retinol Disruption and The Role of Vitamin A Metabolism in Colon Cancer

347

Crossroads: The Role of Biomarkers in the Management of Lumps in the Breast

348

Defining the Complexity of EGFR Endocytosis in Cancer

349

Differential Silencing of STAT3 Isoforms Leads to Changes in STAT3 Activation

350

Tumor Necroptosis Promotes Metastasis by Modulating Tumor-Host Immunity

351

CA 19-9 and CEA in Prognosis of Duodenal Adenocarcinoma: A Retrospective Study

352

The Evolution of Metastatic Cancer: Mechanisms and Drivers

353

Cancer Prevention with Rapamycin

354

Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial

355

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

356

Cancer-Associated Fibroblasts: Challenges and Opportunities

357

Impact of Cortactin in Cancer Progression

358

Oncotarget at AACR Annual Meeting 2023

359

Targeting Pre-Leukemic Cells: New Hope for Preventing Childhood B-ALL

360

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

361

Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

362

Attenuation of Cancer Proliferation by Suppression of Glypican-1

363

Unlocking the Potential of Molecular-Driven Stratification of Osteosarcoma

364

Unconventional Protein Secretion (UPS) in Cancer

365

MTAP Loss in Metastatic Breast Cancer Patients: Genomic Landscape

366

Selective Protection of Normal Cells From Chemotherapy, While Killing Drug-Resistant Cancer Cells

367

Mitochondria Engage the Integrated Stress Response to Promote Tumor Growth

368

HALP Score: Prognostic Ability in Cancers - A Literature Review

369

Unveiling the Non-Canonical Functions of EZH2 in Prostate Cancer

370

The Role of Kras and Canonical Wnt Pathways in Biliary Tract Cancers

371

WNT-pathway Medulloblastoma: What Constitutes Low-risk and How Low Can One Go?

372

Oncogenic Driver FGFR3-TACC3 Requires 5 Coiled-coil Heptads to Activate and Disulfide Bonds

373

Oncotarget’s Top 10 Papers In 2022 (Crossref Data)

374

Phenotype Approach IDs Rare ATR Variants as Potential Male Breast Cancer Susceptibility Alleles

375

Controlling Glycolytic Flux: Therapy Challenges and Solutions

376

Novel Prognostic Index to Predict Survival Outcomes in Gastric Cancer Patients

377

Everolimus Inhibits Angiogenesis, Lymphangiogenesis in TP53 Mutant HNSCC

378

Immunoregulatory Protein CD200 as Potentially Lucrative Yet Elusive Cancer Therapy Target

379

The Importance of CD56 in the Fight Against Multiple Myeloma

380

Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)

381

Intraventricular Immunovirotherapy; A Translational Step Forward

382

The Chromatographic Constitution of Andiroba Oil and its Healing Effects…

383

Researchers Identify New Drug Candidates To Treat DLST+ Tumors

384

Targeting CD74 in B-Cell Non-Hodgkin Lymphoma With Antibody-Drug Conjugate STRO-001

385

Calcium Signaling Induced by 15-deoxy-prostamide-J2 Promotes Cell Death by...

386

Impact of Covid-19 on Management of Patients With Metastatic Melanoma

387

Anti-PD-1 Immune Checkpoint Therapy Resistance, Macrophages and the Wnt Pathway

388

Novel Antibody Drug Conjugate Improves Murine Acute Myeloid Leukemia

389

Serum microRNAs as New Criteria for Referral to Early Palliative Care Services

390

Role of Pyrethroid Derivatives in Autophagy and Apoptosis Crosstalk Signaling

391

Plasma Growth Hormone in HCC as Biomarker of Response to Atezolizumab & Bevacizumab

392

A New Method of Targeting Exosomes in Precision Medicine

393

Behind the Study: APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

394

Plasma Growth Hormone in HCC: A Biomarker of Response to Atezo/Bev?

395

p-STAT3 & c-Myc Correlate With P2-HNF4α Expression in Nonalcoholic Fatty Liver Disease

396

Essential Amino Acids as Diagnostic Biomarkers of Hepatocellular Carcinoma

397

Myeloid-Derived Suppressor Cells: Cancer, Autoimmune Diseases, and More

398

Treasures From Trash In Cancer Research

399

APOE Genotype Determines Cancer Patients Most Likely to Benefit From Exercise

400

Mutation Analysis of Newly-Diagnosed Germinal Center Aggressive B Cell Lymphomas